Table 4.
Ongoing trials on drugs used in gout and other rheumatological diseases
| Drug studied | Official title (acronym) | NCT identifier | Primary outcome measure | Status, expected completion |
|---|---|---|---|---|
| Colchicine | A 2 × 2 factorial randomized controlled trial of colchicine and spironolactone in patients with ST-elevation myocardial infarction (STEMI)/SYNERGY Stent Registry (CLEAR SYNERGY) | NCT03048825 | Major adverse cardiovascular effects | Recruiting, December 2021 |
| The Canadian study of Arterial inflammation in patients with Diabetes and recent vascular events: EvaluatioN of Colchicine Effectiveness (CADENCE) | NCT04181996 | Change in the FDG uptake of tissue-to-blood ratio as a marker of arterial plaque inflammation in the maximally diseased segment of imaged vasculature (carotid or aorta) over a period of 6 months | Not yet recruiting, December 2023 | |
| Impact of Short-course Colchicine Versus Placebo After Pulmonary Vein Isolation: A Pilot Study, (IMPROVE-PVI Pilot) | NCT04160117 | Average monthly number of patients enrolled | Recruiting, January 2022 | |
| Colchicine Prevents Myocardial Injury After Non-Cardiac Surgery Pilot Study (COPMAN) | NCT04139655 | Number of patients included in 3 months after the run-in period | Recruiting, October 2021 | |
| Colchicine for the Prevention Of Perioperative Atrial Fibrillation in Patients Undergoing Thoracic Surgery (COP-AF) | NCT03310125 | Atrial fibrillation within 14 days of randomization | Recruiting, June 2022 | |
| Hypouricemic agents | A phase 2, MulticEnter, double-blind, THree-arm, placebo and active control efficacy and safetY STudy to evaluate verinurad combined with allopurinol in heart failure with preserved ejection fraction (AMETHYST) | NCT04327024 | Effect of verinurad and allopurinol on exercise capacity by measurement of VO2 change over 28 weeks | Not yet recruiting, September 2021 |
| Anti-inflammatory agents | Phase 3, double-blind, placebo-controlled, randomized withdrawal study with open-label extension, to assess the efficacy and safety of rilonacept treatment in subjects with recurrent pericarditis (RHAPSODY) | NCT03737110 | Time to recurrence of pericarditis | Active but not recruiting, June 2021 |
| Treatment of Acute Pericarditis with Anakinra (none) | NCT03224585 | Change in pain, measured by Visual Analog Score, within 6–12 h | Active, not recruiting, March 2021 |